TheraRadar
← Back
Data updated: Jun 28, 2026

COSMO TECHNOLOGIES

Pharma
OncologyImmunologyGastroenterology Execution: Excellent

COSMO TECHNOLOGIES is a pharmaceutical company focused on Oncology, Immunology, Gastroenterology. Key products include AEMCOLO.

2018
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

FDA Novel Drug Designations

(2018)
1 Novel 1 Priority Review 1 Fast Track
See 1 novel approval →
2018 AEMCOLO (RIFAMYCIN SODIUM) Priority Review · Fast Track

COSMO TECHNOLOGIES at a Glance

  • Strong track record with 100% execution quality across 8 trials
  • Fast trial execution (22 months median completion)

COSMO TECHNOLOGIES's Key Drugs

COSMO TECHNOLOGIES's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

COSMO TECHNOLOGIES's Recent FDA Approvals

New NDA/BLA approvals for COSMO TECHNOLOGIES over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

COSMO TECHNOLOGIES's Therapeutic Areas

COSMO TECHNOLOGIES's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 60%
0 drugs Phase 3: 1 Phase 2: 1
Immunology 20%
0 drugs Phase 2: 1
Gastroenterology 20%
0 drugs Phase 2: 1

COSMO TECHNOLOGIES's Top Competitors

COSMO TECHNOLOGIES's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Oncology, Immunology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology
Takeda big-pharma
Immunology, Gastroenterology, Oncology
Pfizer big-pharma
Oncology, Immunology
PF PRISM CV big-pharma
Oncology, Immunology, Gastroenterology

COSMO TECHNOLOGIES Pipeline Snapshot

COSMO TECHNOLOGIES has 4 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 3 Phase 2 and 0 Phase 1.

1
Phase 3
3
Phase 2
0
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 2/2 completed
  • • Speed: 22 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges